Clinical cellular cardiomyoplasty: technical considerations.
Three patients, all with a history of coronary heart disease, underwent coronary artery bypass grafting and implantation of autologous satellite cells. Satellite cells were isolated from muscle biopsies of the right vastus lateralis muscle after enzymatic treatment. While the heart was still under hypothermic cardioplegia, 4 mL of cell suspension divided into approximately 40 doses was injected into the ventricular wall of the ischemic area. Less than 5 minutes were required to complete the cell implantation. All patients survived the procedure, without obvious arrhythmia, had an uneventful recovery, and were discharged from the hospital. At 3 to 4 months follow-up examination, increased left ventricular ejection fraction, decreased left ventricular diastolic diameter, as well as improved ventricular wall thickness and perfusion at the satellite cell implantation sites were observed. Our experience indicated the safety and early benefit of cellular cardiomyoplasty using autologous satellite cells.
Zhang
Fumin
F
The First Affiliated Hospital of Nanjing Medical University, Nanjing, P.R. China.
Yang
Zhijian
Z
Chen
Yijiang
Y
Qin
Jianwei
J
Zhu
Tiebing
T
Xu
Di
D
Xu
Zhaoqiang
Z
Xu
Qingbin
Q
Qian
Yi
Y
Ma
Wenzhu
W
Chen
Lizhen
L
Gao
Xiang
X
Li
Chuanfu
C
Ha
Tuanzhu
T
Kao
Race L
RL
D000368:Aged; D006328:Cardiac Catheterization; D018421:Cardiomyoplasty / Q000379:methods*; D003131:Combined Modality Therapy; D001026:Coronary Artery Bypass / Q000379:methods*; D003324:Coronary Artery Disease / Q000175:diagnosis* / Q000601:surgery*; D015150:Echocardiography, Doppler; D004562:Electrocardiography; D006334:Heart Function Tests; D006439:Hemodynamics / Q000502:physiology; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000166:cytology; D011379:Prognosis; D018570:Risk Assessment; D012494:Sampling Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome